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Abstract
Spontaneous regression of cancer is a rare, but well documented, phenomenon. We present a unique
case of an 82 year old Chinese male who experienced spontaneous regression of histologically-
verified metastatic type II papillary renal cell carcinoma in the absence of intervening systemic therapy
or surgery. This is the first reported case of spontaneous regression of papillary renal cell carcinoma.
The mechanism of spontaneous regression remains unknown, and represents a challenge for existing
oncology paradigms.
Introduction
Renal cell carcinoma (RCC) accounts for 3% of all new
cancer cases worldwide with a rising incidence [1]. The first
reported case of spontaneous regression of metastatic RCC
was published in 1928 [2]. Since then, multiple case
reports and small series have highlighted this rare but
definite phenomenon. The frequency of this phenomenon
is estimated to be <1%. Further limiting available data,
most reported instances of spontaneously regressed
metastases do not have histologic confirmation. In most
reports, the regression occurs shortly after a nephrectomy
[3]. Almost all documented cases of spontaneous
regression of RCC are reported to occur in the metastasis
rather than the primary lesion. Herein, we present a
cytologically verified case of lung metastasis following
relapse from papillary RCC, which regressed sponta-
neously over twelve months without therapy.
Case presentation
A 75 year-old Singaporean male of ethnic Chinese origin
was diagnosed with localized right-sided RCC following a
work-up for an elevated creatinine level (134 umol/L)
discovered on routine health screening. Computed tomo-
graphic (CT) scanning of the lungs did not reveal any
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dissection was performed, and histology revealed a high-
grade Type II papillary RCC (Figure 1A), with sarcomatoid
change (Figure 1B). Tumor invasion of the renal vein and
renal pelvis was noted (Figure1C) with afinal stage of IIIB.
The patient was placed on surveillance with regular chest
X-rays for the first 3 years of follow-up, with yearly visits
thereafter.6yearsfollowingsurgery,CTscanningrevealeda
single solid pulmonary lesion in the left lower lobe of the
lung (Figure 2A) with no other sites of disease. A
percutaneous biopsy of this lesion yielded papillary RCC
(Figure1D).Wedgeresectionofthenodulewasoffered,but
was declined by the patient. No systemic therapy was
offered to the patient as there was no established standard
of care for metastatic non-clear cell RCC at that point in
time, and he did not consume any new drugs or
supplements. Over the next 12 months, imaging revealed
spontaneous regression of the lesion (Figure 2B). He
remainsfreeofprogressivedisease24monthsafterrelapse.
Discussion
Since the first observation of spontaneous regression in
1928 [2], there has been little or no advance in our
understanding of this unusual phenomenon in cancer.
The actual incidence of spontaneous regression of kidney
cancer is poorly understood, as there is little information
on the true denominator of patients with RCC. While
spontaneous regression of clear cell RCC is recognized as a
rare phenomenon, spontaneous regression of papillary
RCC has not been previously reported. Our institutional
database of RCC has a series of 80 patients with papillary
RCC over approximately 20 years, none of whom
exhibited spontaneous regression.
The mechanism for spontaneous regression of metastasis
from RCC is unknown. The favored hypothesis to date is
that spontaneous regression occurs due to immunological
factors, including the removal of a prometastatic or growth
factor secreted by the tumour resulting in apoptosis [4]. In
observed regressions of RCC, regressions have occurred
following plasma infusion from patients who have
experienced a regression, suggesting that humoral factors
may play a role [5]. Cytokines, namely interferon and
interleukin 2 exert anti-tumour affects by for example,
inhibiting angiogenesis of the tumour [5].
It has been speculated that resection of the primary
tumour may result in the removal of a systemic
stimulatory growth factor and thus directly result in
regression [4]. Our case report demonstrating progression
and regression of relapsed tumor many years after
nephrectomy suggests that this mechanism may not be
responsible for all cases of regression.
To date, few reports of spontaneous regression of RCC
have pathological documentation, and even fewer docu-
ment the specific subtype. A review we undertook of these
case reports indicate either a clear cell subtype or do not
specify the subtype (references available on request). The
issue of subtyping in RCC is particularly important.
Metastatic clear cell RCC may occasionally undergo a
durable complete remission following high dose inter-
leukin-2 therapy, but this is not recognized in non-clear
cell RCC including papillary RCC, supporting an immu-
nologic mechanism in spontaneous regression of clear cell
Figure 2. (A) The pulmonary metastasis in the left lower
zone of the lung 6 years post-nephrectomy. (B) A CT scan
one year post relapse showing near complete regression of
the lesion.
Figure 1. (A) Papillary RCC composed of fibrovascular
fronds covered by cells with pink cytoplasm. Inset shows high
magnification of the cells lining the fronds, revealing cytologic
nuclear atypia and oncocytic cytoplasm (type II features). (B)
Sarcomatoid component of the RCC, with loosely aggregated
epithelioid and spindled pleomorphic cells with occasional
multinucleation. Accompanying inflammatory cells are
present. (C) Tumour thrombus within the renal vein. (D)
Fine needle aspiration cytology of the lung lesion, revealing
morular, loosely cohesive clusters of abnormal epithelial cells
(Diff-Quik). Inset shows a PAP stained finger-like
conglomerate of cells with enlarged vesicular nuclei and
prominent nucleoli, in keeping with metastatic papillary RCC.
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spontaneous regression observed in a patient with
papillary RCC. Homozygous inactivation of the von
Hippel-Lindau (VHL) gene is a common molecular
abnormality in both sporadic and familial forms of clear
cell carcinomas, with a resulting dysregulation of the
hypoxia response pathway, increased angiogenesis and
tumour growth [7]. Underlying pathways driving papillary
RCC growth are less well established. Metabolic signaling
has been implicated through the identification of a
familial cancer syndrome including type 2 papillary RCC
from an underlying germline mutation in the fumarate
hydratase (FH) gene, and different activation patterns of
cell cycle pathways between type I and type II papillary
RCC have been reported [8]. Both clear cell RCC and
papillary RCC are thought to be of tubular origin [9].
Sarcomatoid variants of RCC are biologically very aggres-
sive tumours that respond poorly to immunotherapy [10].
It is thought that sarcomatoid change represents an active
area of epithelial- mesenchymal transition. Our patient
had a high grade papillary RCC with sarcomatoid change
and renal vein invasion relapsing only 6 years later, which
was quite unexpected. Whether this long disease-free
interval is directly relevant to spontaneous regression is a
matter for speculation.
When the patient was evaluated initially at relapse, there
was no standard of care for systemic therapy for metastatic
non-clear cell RCC, and he was placed on observation. In
recent years, targeted therapies in this patient group have
been studied with some success, these agents including
temsirolimus [11], sunitinib and sorafenib [12].
In summary, we report the first case of spontaneous
regression in a patient with relapsed metastatic papillary
RCC undergoing surveillance.
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